New approaches to reversal of neuromuscular block

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 5, 2002, Pages 793-800

  Bom, Anton ^a   Clark, John K ^a   Palin, Ronald ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Acetylcholinesterase inhibitors; Anesthesia; Cyclodextrins; Muscle relaxants; Neuromuscular block; Reversal

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMINOPYRIDINE; ATROPINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CISATRACURIUM; CURARE DERIVATIVE; CYCLODEXTRIN; DONEPEZIL; EDROPHONIUM; GALLAMINE; GLYCOPYRRONIUM BROMIDE; MIVACURIUM; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; MUSCLE RELAXANT AGENT; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PHYSOSTIGMINE; PYRIDINIUM DERIVATIVE; PYRIDOSTIGMINE; RAPACURONIUM BROMIDE; ROCURONIUM; SUXAMETHONIUM; TETRYLAMMONIUM; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; VECURONIUM;

ANESTHETIC RECOVERY; CHELATION; COMPETITIVE INHIBITION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG STRUCTURE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; REVIEW; SYNAPTIC MEMBRANE;

ACETYLCHOLINE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR NONDEPOLARIZING AGENTS; POTASSIUM CHANNEL BLOCKERS;

EID: 0036771227     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Läwen A: Über die Verbindung Lokalanaesthesie mit der Narkose, über hohe Extradural Anaesthesie und epidurale Injektionen anaesthesierende Loesungen bei tabetischen Magenkriesen. Beitrage Klinische Chirurgie (1912) 80:168-169.
2. Griffith HR, Johnson GE: The use of curare in general anesthesia. Anesthesiology (1942) 3:418-420.
3. Booij LHDJ (Ed): Fundamentals of Anaesthesia and Acute Medicine: Neuromuscular Transmission. BMJ Publishing Group, London, UK (1996). An excellent background to current clinical practice in anesthesia.
4. Savarese JJ, Caldwell JE, Lien CA, Miller RD: Pharmacology of muscle relaxants and their antagonists. In: Anesthesia, 5th Edition. Miller RD (Ed), Churchill-Livingstone, Philadelphia, PA, USA (2000):412-490. This section of the latest updated edition of this comprehensive text describes current use of AChE inhibitors in the clinic.
5. Mayrhofer OK: Self-experiments with succinylcholine chloride: A new ultra-short-acting muscle relaxant. Br Med J (1952) 2:1332-1334.
6. Böhm R: Über Curare und Curarealkaloide. Arch Pharmacol Berlin (1897) 235:660-664.
7. Viby-Mogensen J, Jørgensen BC, Ørding H: Residual curarization in the recovery room. Anesthesiology (1979) 50:439-441. This paper is an early description of the problems associated with post-surgery residual curarization, revealed by detailed monitoring.
8. Pedersen T, Viby-Mogensen J, Eliasen K, Ringsted C, Henriksen E: A one year prospective study of postoperative pulmonary complications after neuromuscular blockade by pancuronium and atracurium. Anesthesiology (1988) 69(Suppl):A902.
9. Ballantyne JC, Chang Y: The impact of choice of muscle relaxant on postoperative recovery time: A retrospective study. Anesth Analg (1997) 85:476-482.
10. Bevan DR, Donati F, Kopman AF: Reversal of neuromuscular blockade. Anesthesiology (1992) 77:785-805. A comprehensive review of the reversal of NMB.
11. Harper NJN, Pollard MJ (Eds): Reversal of neuromuscular block. In: Muscle Relaxants in Anaesthesia. Edward Arnold Editions, London, UK (1995) 8:135-155.
12. Kensler CJ: The anticurare activity of tetraethylammonium in the cat. Br J Pharmacol (1950) 5:204-209.
13. Paskov DS, Agoston S, Bowman WC: 4-aminopyridine hydrochloride (Pymadin). In: New Neuromuscular Blocking Agents. Handbook of Experimental Pharmacology. Kharkevich DA (Ed), Springer Verlag, Berlin, Germany (1986) 79:679-717.
14. Agoston S, Langreter D, Newton DEF: Pharmacology and possible clinical applications of 4-aminopyridine. Semin Anesth (1985) 4:81-86.
15. Pal J: Physostigmin, ein Gegengift des Curare. Zeitschrift der Physiologie (1900) 14:255-258.
16. Laquer L: Über eine neue therapeutische Verwendungs des Physostigmin. Zentr Med Wissenschaft (1876) 14:421-422.
17. Stedman E, Barger G: Physostigmine (Eserine). J Chem Soc (1925) 127:247-258.
18. Julian PL, Pikl J: Studies in the indole series III: On the synthesis of physostigmine. J Am Chem Soc (1935) 57:539-544.
19. Aeschlimann J, Reinert M: Pharmacological action of some analogues of physostigmine. J Pharmacol Exp Ther (1931) 43:413-444.
20. Endou M, Tanito Y, Okumura F: A comparison between chronotropic effects of neostigmine and edrophonium in isolated guinea pig right atrium. J Pharmacol Exp Ther (1997) 282:1480-1486.
21. Kaur J, Zhang MQ: Molecular modelling and QSAR of reversible acetylcholinesterase inhibitors. Curr Med Chem (2000) 7:273-294.
22. Grove SJ, Kaur J, Muir AW, Pow E, Tarver GJ, Zhang MQ: Oxyaniliniums as acetylcholinesterase inhibitors for the reversal of neuromuscular block. Bioorg Med Chem Lett (2002) 12:193-196.
23. Brufani M, Filocamo L, Lappa S, Maggi A: New acetylcholinesterase inhibitors. Drugs Future (1997) 22:397-410.
24. Kawakami Y, Inoue A, Kawai T, Wakita M, Sugimoto H, Hopfinger AJ: The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem (1996) 4:1429-1446.
25. Clark JK, Cowley P, Muir AW, Palin R, Pow E, Prosser AB, Taylor R, Zhang M-Q: Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block. Bioorg Med Chem Lett (2002):12:2565-2568.
26. Palin R, Clark JK, Cowley P, Muir AW, Pow E, Prosser AB, Taylor R, Zhang M-Q: Novel piperidinium and pyridinium agents as water-soluble acetylcholinesterase inhibitors for the reversal of neuromuscular blockade. Bioorg Med Chem Lett (2002):12:2569-2572.
27. Fisher DM, Canfell PC, Fahey MR, Rosen JI, Rupp SM, Sheiner LB, Miller RD: Elimination of atracurium in humans: Contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology (1986) 65:6-12.
28. Stovner J, Stadskleiv K: Suxamethonium apnoea terminated with commercial serumcholinesterase. Acta Anaesthesiol Scand (1976) 20:211-215.
29. Naguib M, el-Gammal M, Daoud W, Ammar A, Moukhtar H, Turkistani A: Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade. Anesthesiology (1995) 82:1288-1292.
30. Naguib M, Samarkandi AH, Bakhamees HS, Turkistani A, Alharby SW: Edrophonium and human plasma cholinesterase combination for antagonism of mivacurium-induced neuromuscular block. Br J Anaesth (1996) 77:424-426.
31. Naguib M, Selim M, Bakhamees HS, Samarkandi AH, Turkistani A: Enzymatic versus pharmacologic antagonism of profound mivacurium-induced neuromuscular blockade. Anesthesiology (1996) 84:1051-1059.
32. Naguib M, Daoud W, el-Gammal M, Ammar A, Turkistani A, Selim M, Altamimi W, Sohaibani MO: Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase. Anesthesiology (1995) 83:694-701.
33. Gyermek L, Cho YM, Nguyen N, Lee C: Neuromuscular blocking N,N′-polymethylene bistropanium, 3αhydroxytropanium and bis-3-oxotropanium compounds. Life Sci (1998) 63:PL303-PL309.
34. Gyermek L, Cho YM, Nguyen N: Neuromuscular blocking bis tropinium glutarate diesters: Optimisation of the benzyl quaternary groups. Anesth Analg (2001) 92:S199.
35. Gyermek L, Lee C, Cho YM, Nguyen N, Tsai SK: Neuromuscular pharmacology of TAAC3, a new nondepolarizing muscle relaxant with rapid onset and ultrashort duration of action. Anesth Analg (2002) 94:879-885. The paper presents the most recent results in the quest for ultra-short acting neuromuscular blockers, discovered after optimization of the bistropaninium series of compounds.
36. Kaldor I, Feldman PL, Mook RA Jr, Ray JA, Samano V, Selfer AM, Thompson JB, Travis BR, Boros EE: Stereocontrolled synthesis of cis-dibenzoquinolinizine chlorofumarates: Curare-like agents of ultrashort duration. J Org Chem (2001) 66:3495-3501.
37. Boros EE, Bigham EC, Boswell GE, Mook Jr RA, Patel SS, Savarese JJ, Ray JA, Thompson JB, Hashim MA, Wisowaty JC, Feldman PL, Samano VV: Bis- and mixedtetrahydroisoquinolinium chlorofumarates: New ultra-shortacting nondepolarising neuromuscular blockers. J Med Chem (1999) 42:1114. This paper presents further refinements of a tetrahydroisoquinolinium series, using a chlorofumarate linker to give a neuromuscular blocker with ultra-short time course.
38. Gotta AW: American Society of Anesthesiologist 1999 Annual Meeting (Part II). Dallas, TX, USA IDdb3 Meeting Report (1999) October 9-13. www.iddb3.com
39. Legal information. Prous Science, Barcelona, Spain. www.prous.com/legal.html
40. Bom A, Bradley M, Cameron K, Clark JK, Egmond J van, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang M-Q: A novel concept of reversing neuromuscular block: Chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed (2002) 41:265-270. This is the first report demonstrating that host-guest chemistry can provide a potent pharmacological agent, both in vitro and in vivo.
41. Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, Palin R, Prosser A, Rees DC, Rosair GM, Stevenson D et al: Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: Synthesis and structure-activity relationships. J Med Chem (2002) 45:1806-1816. This paper describes the structure-activity of functionalized cyclodextrin derivatives with high binding affinity for rocuronium bromide, and the resultant rapid reversal of NMB.
42. Detwiler PB: The effects of germine-3-acetate on neuromuscular transmission. J Pharmacol Exp Ther (1972) 180:244-254.
43. Standaert FG, Detwiler PB: The neuromuscular pharmacology of germine-3-acetate and germine-3,16diacetate. J Pharmacol Exp Ther (1970) 171:223-241.
44. Voogd TE, Vansterkenburg E, Wilting J, Janssen LH: Recent research on the biological activity of suramin. Pharmacol Rev (1993) 45:177-203.
45. 2purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol (1988) 93:243-245.
46. Henning RH, Nelemans A, Scaf AH, Van Eekeren J, Agoston S, Den Hertog A: Suramin reverses non-depolarizing neuromuscular blockade in rat diaphragm. Eur J Pharmacol (1992) 216:73-79.
47. Henning RH, Nelemans A, Houwertjes M, Agoston S: Reversal by suramin of neuromuscular block produced by pancuronium in the anaesthetized rat. Br J Pharmacol (1993) 108:717-720.
48. Henning RH, Rowan EG, Braga MF, Nelemans A, Harvey AL: The prejunctional inhibitory effect of suramin on neuromuscular transmission in vitro. Eur J Pharmacol (1996) 301:91-97.
49. Geh SL: Reversibility of the neuromuscular blocking effects of active components of the malayan cobra (naja naja sputatrix) venom in the presence of heparin. Asia Pacif J Pharmacol (1991) 6:81-85.
50. ORGANON LABORATORIES LTD (Bom A, Muir A, Rees DC): drug-induced neuromuscular block. WO-00112202 (2001).
51. ORGANON LABORATORIES LTD (Zhang M-Q, Palin R, Bennet JD): 6-Mercapto-cyclodextrin derivatives: Reversal agents for drug-induced neuromuscular block. WO-00140316 (2001).